2021-01-04,Orphazyme to take part in panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
2020-12-31,CytRx Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C
2020-12-27,Orphazyme provides regulatory update on arimoclomol for NPC
2020-12-10,"Kim Stratton, CEO, resigns from Orphazyme"
2020-12-09,Financial calendar 2021
2020-12-07,CytRx Announces Orphazymes U.S. Expansion Ahead of Potential Regulatory Approval of Arimoclomol for Niemann-Pick Disease Type C
2020-12-02,Orphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization
2020-11-30,Is Orphazyme (ORPH) A Good Stock To Buy Now?
2020-11-09,Orphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C
2020-11-03,End of stabilization period
2020-10-27,Stabilization measures taken
2020-10-23,Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020
2020-10-21,Dozens of volunteers to be deliberately infected with COVID-19 in effort to speed up vaccine development
2020-10-16,Stabilization measures taken
2020-10-09,Major shareholder announcement
2020-10-08,Stabilization measures taken
2020-10-05,Major shareholder announcement
2020-10-05,Major shareholder announcement
2020-10-02,Reporting of transactions in Orphazymes shares made by persons discharging managerial responsibilities
2020-10-01,"Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe"
2020-09-30,"Orphazyme files final prospectus in connection with a global offering, consisting of initial public offering of American Despositary Shares in the United States and concurrent private placement of ordinary shares in Europe"
2020-09-30,"Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering"
2020-09-28,Stabilization period begins
2020-09-28,"Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe"
2020-09-25,Orphazyme A/S provides update onÂ previously announced global offering
